ClinicalTrials.gg
RecruitingNCT05584007COATUpdated May 15, 2026

Cellulitis Optimal Antibiotic Treatment

A Phase 3 interventional study of Flucloxacillin Only Product in Oral Dose Form and Placebo Only Product in Oral Dose Form in Cellulitis of Leg, sponsored by University of Southampton. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by University of Southampton · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
334
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 258 studies in Pain with a site in United Kingdom — 18 open to participants now, 19 under way, 1 of them phase 3. Pain · United Kingdom.

Planned enrollment
31st of 214
334 · median 78
Started
2023
with 14 others
Phase 3
60 of 258
1 open now
Primary completion
2026-05
later than 8 of 18 live
Registered
217th of 258
by date

Among the 258 studies in Pain with a site in United Kingdom, this one is the 31st largest by planned enrollment of the 214 interventional ones that give a count, is one of 15 that started in 2023, is one of 60 in phase 3, reaches primary completion later than 8 of the 18 other live ones, and was the 217th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

18 of the 258 studies in Pain with a site in United Kingdom are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 258 studies in Pain with a site in United Kingdom, or all of them as a file.
02

Study summary

To determine whether a short course of oral flucloxacillin (5 days) is non-inferior to a standard course (7 days) in terms of pain over days 6-14 (indicative of persistence or recurrence associated with the symptoms of most importance to patients) in adults with cellulitis of the leg presenting in primary care.

Read the detailed description

Cellulitis is a deep infection of the skin and subcutaneous tissues and most often occurs in the legs. It is a painful condition that is associated with inflammation and swelling of the site, and often systemic symptoms such as fever, headache, muscle aches, malaise, and fatigue. Patients report feeling unwell and that it has a significant impact on their mobility and ability to carry out their usual activities. NICE guidelines recommend oral flucloxacillin 500-1000 mg four times daily for 5-7 days as first-line treatment for most patients with cellulitis in the community, but most prescriptions are dispensed for a 7-day course. We will be assessing the effectiveness and safety of a 5-day treatment vs. the standard 7-day treatment. We also aim to evaluate the cost-consequences of a shorter course from an NHS and personal perspective. Participants will be randomly allocated to one of two groups. In addition to usual care, participants will either be assigned to a 5-day oral flucloxacillin course or a standard 7-day flucloxacillin course. Participants will be prescribed a 5-day course of oral flucloxacillin, and two additional tablets will be posted to the participants which will either be the antibiotic or a placebo tablet. Participants will be asked to fill out daily questionnaires and express their experiences with the shortened course and taking part in the trial.

03

Conditions studied

  • Cellulitis of Leg

Browse trials for

Keywords

  • Primary care
  • Antibiotic treatment
  • Antibiotic resistance
  • Pain
  • Cost consequences
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be aged 18 years or older
  • Currently showing symptoms of cellulitis (such as pain, tenderness, redness, other change in skin color, warmth to touch) in one leg for 10 days or less
  • Pain rated as 3/10 or higher on a numerical rating scale (0-10) at baseline assessment
  • Be willing to be randomized to either trial arm (5-day or 7-day treatment)
  • Able to complete trial procedures in the English language.

Exclusion criteria

Exclusion Criteria:

  • Have penicillin allergy
  • Have bilateral cellulitis
  • Have had antibiotics for cellulitis within the past month
  • Have post-operative cellulitis (within 30 days of operative procedures on the same leg)
  • Have cellulitis resulting from human/animal bite injury
  • Have Cellulitis associated with chronic (>6 weeks) leg ulceration
  • Require immediate hospital admission or out-patient intravenous antibiotic therapy
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
334 participants (estimated)

Study arms

  • Placebo comparator
    Intervention

    Flucloxacillin 500mg four times a day (QDS) for 5 days (unblinded NHS prescription) followed by blinded placebo QDS for 2 days (5 days of antibiotic)

    Drug: Flucloxacillin Only Product in Oral Dose Form · Drug: Placebo Only Product in Oral Dose Form

  • Active comparator
    Control

    Flucloxacillin 500mg QDS for 5 days (unblinded NHS prescription) followed by flucloxacillin 500mg QDS (blinded) for 2 days (7 days of antibiotic)

    Drug: Flucloxacillin Only Product in Oral Dose Form

Interventions

  • DrugFlucloxacillin Only Product in Oral Dose Form

    Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by blinded flucloxacillin 500mg for 2 days, reaching a total of 7 days of antibiotic treatment

  • DrugPlacebo Only Product in Oral Dose Form

    Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by a blinded placebo for 2 days, reaching a total of 5 days of antibiotic treatment

06

What researchers measure

Primary outcomes

  1. Pain assessment

    Self-reported pain (measured using the Pain Numeric Rating Scale (0-10))

    Time frame: Days 7-16

Secondary outcomes

  1. Use of additional antibiotics

    Any reported use of antibiotics other than the initial 5 days of flucloxacillin and 2 days of IMP)

    Time frame: Up to day 28

  2. Patient-reported assessment of how well they are feeling

    Numeric rating scale NRS (0-10) and assessed as repeated measures

    Time frame: Days 6-14

  3. Health related quality of life

    EQ-5D-5L - values, and individual dimension (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) level scores using repeated measures.

    Time frame: Days 6-14

  4. Health related quality of life used to estimate Quality Adjusted- Life Years (QALYs)

    EQ-5D-5L - values, and individual dimension (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) level scores using repeated measures.

    Time frame: Days 6-14

  5. Leg swelling and warmth

    Participant reported questionnaire

    Time frame: Day 7, 14, 21, 28

  6. Time until self-reported recovery

    Participant reported questionnaire

    Time frame: Day 7, 14, 21, 28

  7. Time until self-assessed extent of cellulitis starts to reduce (with no subsequent increase)

    Participant reported questionnaire

    Time frame: Day 7, 14, 21, 28

  8. Hospital admissions

    Number of hosptial admissions since randomisation, collected from primary care notes review

    Time frame: 12 months

  9. Recurrent cellulitis episodes over 12 months (number of episodes)

    Recurrent cellulitis episodes over 12 months (number of episodes) since randomisation, collected from primary care notes review

    Time frame: 12 months

  10. Complications over 12 months

    Number of reported complications since randomisation, collected from primary care notes review

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Royal South Hants Hospital
    Southampton, United Kingdom
    Recruiting
    • Ian Ward · Contact
    • Ian Ward · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Data from all centers will be analyzed together and published as soon as possible. Planned publication of the results in a high-impact peer-reviewed journal. Planned publication of protocol in a peer-review journal. The datasets generated and/or analyzed during the current study will be published as a supplement to the publication of the results. Individual investigators may not publish data concerning their patients that are directly relevant to questions posed by the trial until the Trial Management Group (TMG) has published its report. The TMG will form the basis of the Writing Committee and advise on the nature of publications.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for May 2026, 33 months after the start.

Of 111 non-industry phase 3 interventional studies under Pain, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 33 months is close to that.

Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2022
First posted
Oct 18, 2022
StartActual
Aug 29, 2023
Primary completionEst.
May 2026
CompletionEst.
Jul 2027
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05584007
Collaborators
University of East Anglia, University of Nottingham, Norfolk and Norwich University Hospitals NHS Foundation Trust, University Hospital Southampton NHS Foundation Trust
Responsible party
Sponsor
First posted
Oct 18, 2022
Start date
Aug 29, 2023
Primary completion
May 2026 (estimated)
Completion
Jul 2027 (estimated)
Last update
May 15, 2026

Study contacts

Sophie Varkonyi-Clifford
Contact
coat@soton.ac.uk
0 23 8059 1532
Ella Bourke
Contact
coat@soton.ac.uk
02381550206

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion